A new antibody treatment for acromegaly
Official title: A First-in-Class Therapeutic Antibody for Treatment of Acromegaly
Funded at Elixera, INC. · NIH-11008939 · Data updated 2026-11-12
This study is testing a new treatment for acromegaly that uses a special antibody to help control growth hormone levels, aiming to provide better long-term health for people with this condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Elixera, INC. NIH-funded |
| Lab location | 1 site (Redwood City, United States) |
| Project start | September 5, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,035,589 |
| NIH project number | 2R44DK126579-02A1 |
| Project ID | NIH-11008939 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with acromegaly who have not achieved adequate hormone control with existing treatments.
✕Less likely to help
Patients who have not been diagnosed with acromegaly or those whose condition is adequately managed with current therapies may not benefit from this research.
What this research studies
This research focuses on developing a novel therapeutic antibody aimed at treating acromegaly, a rare endocrine disorder caused by excess growth hormone due to non-cancerous pituitary tumors. The project aims to provide a long-term solution for hormone control, which is currently inadequately addressed by existing therapies. By blocking the activity of growth hormone, this treatment could significantly improve health outcomes for patients suffering from this condition. The research will involve clinical testing to evaluate the effectiveness and safety of this new therapy.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with acromegaly, improving their quality of life and potentially extending their life expectancy.
How similar studies have gone: Other research has shown promise in developing antibody therapies for endocrine disorders, indicating potential success for this novel approach.
Where this research is happening
-
Elixera, INC.
Redwood City, United States Active
Researchers
- Principal investigator: Zanghi, Adiba — Elixera, INC.
- Study coordinator: Zanghi, Adiba
Related research
Other NIH-funded projects on the same topics.
-
A new antibody treatment for acromegaly
A novel antibody medicine aims to lower excess growth hormone in adults with acromegaly to help control symptoms and complications.
-
NTQ6179 tablets first-in-human test in healthy adults
This phase 1 study tests a single oral dose of NTQ6179 vs placebo in healthy adults to see if it is safe and how the body processes the drug.
-
Test MAR002 for acromegaly in adults on or off medical therapy
This study tests whether subcutaneous MAR002 is safe and tolerable in adults with acromegaly, compared with a placebo, over 10 weeks.
-
Octreotide SC Depot in Acromegaly: Real-World Safety and Effectiveness
This study follows people with acromegaly who are using octreotide subcutaneous depot to see how it works and how safe it is over up to two years in everyday clinical practice.
-
MAR002 in healthy men
This trial tests whether a subcutaneous injection of MAR002 is safe and tolerable in healthy men aged 18 to 40.
-
Pasireotide LAR and bone health in adults with acromegaly
This study will test whether switching adults with uncontrolled acromegaly to pasireotide LAR changes bone turnover and the risk of vertebral fractures.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.